First seen on Bench Side Story 7th November 2023
South Australian Health and Medical Research Institute, also known as SAHMRI has had significant impacts in various areas over the past ten years, and this year is celebrating its 10 year anniversary with a week of events.
Executive Director, Professor Maria Makrides spoke to Australian Health Journal about 3 achievements in the past 10 years that have had significant impact
- International leadership breakthroughs in leukaemia research
- Culturally appropriate Indigenous health research and clinical care
- Omega 3 fatty acids as a preterm birth prevention
Looking ahead, SAHMRI is not standing still, and the newly built, and when fully installed, Australian Bragg Centre for Proton Therapy and Research will be Australia’s first proton therapy centre and the first of its kind in the Southern Hemisphere.
The Centre will occupy the ground floor and three below-ground levels of the Australian Bragg Centre building which has recently been completed on the eastern side of the distinctive SAHMRI building on North Terrace, Adelaide.
The centre will also be an integral part in a global network undertaking proton therapy research. Proton therapy is a precise, non-invasive radiotherapy that can destroy cancer cells while minimising damage to surrounding healthy tissue including vital organs.
As a relatively new treatment option and one that remains expensive and not widely available, proton therapy has only been validated against a small range of cancers. The technology is potentially beneficial in treating many other diseases, but more research is needed in these areas to prove its efficacy.
SAHMRI represents an exciting and unique statewide concept, bringing together basic and translational research, South Australia’s three universities and the health system. SAHMRI works in collaboration with its partners to provide a clear focal point for health and medical research, including paving the way for new partnerships, innovative research projects and improved health outcomes.
The career opportunities at SAHMRI for researchers ranges from early career stage to recognised experts in their fields. Nothing unique with that, but the ability to validate discovery makes SAHMRI a unique work environment.
According to Executive Director, Professor Maria Makrides, “The culture is characterised by being fast, focused, friendly, flexible, and fun, which has fostered innovation, collaboration, and the ability to take risks and learn from both successes and failures to make advancements quickly.”
You Might also like
-
Interventional radiologists offer alternative to hysterectomy
In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
-
World-first clinical trial improves patient outcomes for kidney transplants
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.